NDAINTRAVENOUSSOLUTION
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
6
Clinical Trials (5)
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
Started Apr 2021
12 enrolled
End Stage Renal Disease
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
Started Sep 2020
150 enrolled
End Stage Renal Disease
Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.
Started Jun 2020
23 enrolled
End Stage Renal Disease
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Started Oct 2017
27 enrolled
End Stage Renal Disease
Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Started Apr 2016
13 enrolled
End Stage Renal Disease
Loss of Exclusivity
LOE Date
Apr 17, 2029
38 months away
Patent Expiry
Apr 17, 2029
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7816404 | Apr 17, 2029 | Substance | U-2801 |
Company
Rockwell Medical
WIXOM, MI